Xalkori Approval History
FDA Approved: Yes (First approved August 26, 2011)
Brand name: Xalkori
Generic name: crizotinib
Dosage form: Capsules
Company: Pfizer Inc.
Treatment for: Non-Small Cell Lung Cancer
Xalkori (crizotinib) is an oral anaplastic lymphoma kinase (ALK) inhibitor for the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors are ALK-positive or ROS1-positive.
Development History and FDA Approval Process for Xalkori
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.